RAPT Therapeutics (RAPT) to Release Quarterly Earnings on Thursday

RAPT Therapeutics (NASDAQ:RAPT) is expected to be posting its Q1 2025 quarterly earnings results before the market opens on Thursday, May 8th. Analysts expect the company to announce earnings of ($0.31) per share for the quarter.

RAPT Therapeutics (NASDAQ:RAPT) last issued its quarterly earnings data on Thursday, March 6th. The company reported ($1.14) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.45) by ($0.69). On average, analysts expect RAPT Therapeutics to post $-2 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

RAPT Therapeutics Stock Performance

RAPT stock opened at $0.91 on Tuesday. The firm has a fifty day moving average price of $1.05 and a 200 day moving average price of $1.28. RAPT Therapeutics has a fifty-two week low of $0.75 and a fifty-two week high of $8.44. The firm has a market cap of $120.63 million, a PE ratio of -0.33 and a beta of -0.04.

Analyst Ratings Changes

Separately, HC Wainwright restated a “buy” rating and issued a $10.00 target price on shares of RAPT Therapeutics in a report on Monday, March 10th. One investment analyst has rated the stock with a sell rating, six have given a hold rating and two have issued a buy rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and an average price target of $4.00.

About RAPT Therapeutics

RAPT Therapeutics, Inc, a clinical-stage immunology-based biopharmaceutical company, focuses on discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases in the United States. The company's lead inflammation drug candidate is zelnecirnon (RPT193), a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues.